Cabaletta Bio clinical trials we track

Check company identity source

Phase 2 / 3 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate incidence of adverse events. After: Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects.

Planned enrollment increased by 25 participants

Before: 12 participants (planned). After: 37 participants (planned).

Phase changed

Before: PHASE1, PHASE2. After: PHASE2, PHASE3.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate adverse events reported by subjects. After: Measure: Phase 1/2: Incidence and severity of adverse events (AEs) Measure: Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Measure: Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids.

Planned enrollment increased by 50 participants

Before: 24 participants (planned). After: 74 participants (planned).

Phase changed

Before: PHASE1, PHASE2. After: PHASE2, PHASE3.

Check registry source